Compare KKR & Co Inc (KKR) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Tilray Brands Inc — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: KKR & Co Inc is far larger — about 151.5× Tilray Brands Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Tilray Brands Inc for 31 Days on average.
| KKR | TLRY | |
|---|---|---|
Market Cap | $80.39B | $530.54M |
Volume | 6,517,705 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $142.75 | $17.20 |
52-Week Low | $83.88 | $3.54 |
Typical Hold Time | 67 Days | 31 Days |
Enterprise Value | $2.95B | $684.46M |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $89.56, down 0.12% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. Recent earnings show a mixed track record, with Q2 2026 beating estimates but Q4 2025 missing. The company maintains strong analyst support with a consensus price target of $123.30 and 24 buy ratings. Recent news highlights active deal-making, including a joint venture with Thomson Reuters and investments in AI infrastructure, signaling ongoing strategic expansion.
The outlook for KKR is positive based on robust analyst sentiment and strategic investments, but risks include volatile cash flows and high debt levels. Investors may find opportunity in the significant upside to the price target, though macroeconomic sensitivity and execution risks warrant caution.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
